<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="101">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514447</url>
  </required_header>
  <id_info>
    <org_study_id>G1T28-03</org_study_id>
    <nct_id>NCT02514447</nct_id>
  </id_info>
  <brief_title>Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy</brief_title>
  <official_title>Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G1 Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G1 Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to investigate the potential clinical benefit of G1T28 in protecting the
      bone marrow and preserving the immune system when administered prior to topotecan in
      patients previously treated for extensive-stage SCLC.

      The study consists of 2 parts: a limited open-label, dose-finding portion (Part 1), and an
      open-label single arm expansion phase (Part 2). Both parts include 3 study phases: Screening
      Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day
      of first dose with study treatment and completes at the Post-Treatment Visit. Approximately,
      40 patients will be enrolled in the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>Days 1-21 of Cycle 1</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment related adverse events (AE)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile for G1T28 and Topotecan</measure>
    <time_frame>Days 1 and 4 of Cycle 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples for the determination of G1T28 and Topotecan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>24 Months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 Month</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic parameters</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The following will be assessed: hemoglobin, hematocrit, white blood cells with differential and platelet counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response based on RECIST, Version 1.1</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for RBC and platelet transfusions</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for treatment with hematopoietic growth factors</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chemotherapy dose reductions and dose interruptions overall</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>G1T28 + Topotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive G1T28 prior to standard chemotherapy, topotecan. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.
For patients enrolled in Part 1, PK assessments completed on days 1 and 4 in cycle 1 only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G1T28 + Topotecan</intervention_name>
    <description>G1T28, Topotecan</description>
    <arm_group_label>G1T28 + Topotecan</arm_group_label>
    <other_name>G1T28 (CDK 4/6 inhibitor) + Topotecan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged â‰¥18 years

          -  Histologically or cytologically confirmed diagnosis of SCLC, preferably including the
             presence of neuroendocrine features by immunohistochemistry

          -  Progression during or after prior first- or second-line chemotherapy and eligible to
             receive topotecan therapy

          -  At least 1 target lesion that is unirradiated and measurable by RECIST, Version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2

          -  Adequate organ function

        Exclusion Criteria:

          -  Presence of symptomatic brain metastases requiring immediate treatment with radiation
             therapy or steroids.

          -  Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart
             failure

          -  Known history of stroke or cerebrovascular accident within 6 months prior to
             enrollment

          -  Other uncontrolled serious chronic disease or conditions that in the investigator's
             opinion could affect compliance or follow-up in the protocol

          -  Concurrent radiotherapy to any site or radiotherapy within 2 weeks prior to
             enrollment or previous radiotherapy to the target lesion sites (the sites that are to
             be followed for determination of a response)

          -  Receipt of any investigational medication within 2 weeks prior to enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Contact</last_name>
    <role>Study Director</role>
    <affiliation>G1 Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>G1Therapeutics Clinical Contact</last_name>
    <email>clinicalinfo@g1therapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Genesis Cancer Center</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Sellers, RN</last_name>
      <email>lsellers@genesiscancercenter.com</email>
    </contact>
    <investigator>
      <last_name>R. Timothy Webb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital - University of Colorado Health</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caralyn Henderson, RN, BSN</last_name>
      <email>Caralyn.Henderson@uchealth.org</email>
    </contact>
    <investigator>
      <last_name>Robert Hoyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shantal Hobson</last_name>
      <phone>303-285-5075</phone>
      <email>Shantel.Hobson1@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Robert Jotte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health, Oncology Clinical Research Northern Region</name>
      <address>
        <city>Ft. Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlon Bazan</last_name>
      <email>marlon.bazan@uchealth.org</email>
    </contact>
    <investigator>
      <last_name>Steven Schuster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - South</name>
      <address>
        <city>Ft. Myers</city>
        <state>Florida</state>
        <zip>33916</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Solak, RN</last_name>
      <phone>239-938-0800</phone>
      <email>nsolak@flcancer.com</email>
    </contact>
    <investigator>
      <last_name>Lowell Hart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - North</name>
      <address>
        <city>Tavares</city>
        <state>Florida</state>
        <zip>32778</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Biermeier</last_name>
      <phone>727-216-1143</phone>
    </contact>
    <investigator>
      <last_name>Maen Hussein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - East</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Todd Gersten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Cancer and Blood Center, LLC</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Hodgson</last_name>
      <phone>706-353-2990</phone>
      <phone_ext>279</phone_ext>
      <email>jhodgson@universitycancer.com</email>
    </contact>
    <investigator>
      <last_name>Petros Nikolinakos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Taofeek Owonikoko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital - Georgia Cancer Specialists</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anila Lokhandwala</last_name>
      <phone>404-256-4777</phone>
      <phone_ext>9242</phone_ext>
      <email>anila.lokhandwala@gacancer.com</email>
    </contact>
    <investigator>
      <last_name>Rodolfo Bordoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology Associates PC</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma University - Peggy and Charles Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Block</last_name>
      <phone>405-271-8001</phone>
      <phone_ext>48160</phone_ext>
      <email>Ingrid-Block@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Raid Aljumaily, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Johnson</last_name>
      <phone>864-455-3735</phone>
      <email>LJohnson4@ghs.org</email>
    </contact>
    <investigator>
      <last_name>Jeff Edenfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gibbs Cancer Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Kirby</last_name>
      <email>lkirby@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Caio Rocha-Lima, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meharry Medical College</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Thomas, RN</last_name>
      <phone>615-341-4228</phone>
    </contact>
    <investigator>
      <last_name>Phillip Lammers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Spigel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology- Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eric Nadler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Yates</last_name>
      <phone>713-563-0712</phone>
      <email>nsyates@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Reneta Ferrarotto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandi Jackson</last_name>
      <phone>903-579-9800</phone>
      <email>Brandi.Jackson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Donald Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minette Ty</last_name>
      <phone>703-208-3188</phone>
      <email>Minette.Ty@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen McClain</last_name>
      <phone>757-213-5658</phone>
      <email>Karen.McClain@USOncology.com</email>
    </contact>
    <investigator>
      <last_name>Paul Conkling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Welch, RN</last_name>
      <phone>360-449-6522</phone>
      <email>Judith.Welch@USOncology.com</email>
    </contact>
    <investigator>
      <last_name>David Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>March 7, 2016</lastchanged_date>
  <firstreceived_date>July 31, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SCLC</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
